Madrigal Pharmaceuticals enters license pact with CSPC for SYH2086

Madrigal Pharmaceuticals (MDGL) announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026. Under the agreement, CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086. CSPC will receive an upfront payment of $120M and is eligible to receive up to $2Bin milestone payments if certain development, regulatory and commercial milestones are achieved, as well as royalties on net sales. CSPC may develop and commercialize other oral GLP-1 agonists in China subject to certain conditions. The transaction is anticipated to close in the fourth quarter of 2025, subject to the applicable regulatory clearance.